NEW
YORK, March 4, 2024 /PRNewswire/ -- ANEW
MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based
biotechnology company ("ANEW") focused on developing cell and gene-
based treatments to affect aging and age-related diseases,
announced that is has been granted and issued a patent in
China, number CN 117126829 A
for the use of ANEW's Klotho protein and Klotho gene delivery and
expression systems in the treatment of cognition, memory and
neurodegenerative diseases. This intellectual property was licensed
by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE
RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide
basis and ANEW paid for all patent costs associated with obtaining
–the patent.
Dr. Joseph Sinkule, the Founder
and CEO of ANEW stated "Obtaining a patent in China was difficult but important to our
global product development programs in neurodegenerative diseases.
The aging population in China is
affected by the same age-related diseases we are fighting in the US
and Europe. ANEW plans to obtain
patents in Hong Kong and other
Asian markets and seek to establish a distributorship in these
markets with companies in Asia
that can market and sell our products".
In May 2023, ANEW announced its
proposed merger with a special purpose acquisition company ("SPAC")
called Redwoods (NASDAQ: RWOD) ("RWOD" or "Redwoods"). At
closing, anticipated to take place in March
2024, we expect ANEW to be listed on NASDAQ. The CFO of RWOD
and a member of the RWOD Board, Mr. Edward
Cong Wang, will join the ANEW Board of Directors on the
board of the combined company.
About ANEW MEDICAL, INC. - ANEW MEDICAL, INC. (OTC: LEAS) is a
technology and medical product development company focused on the
development of therapeutics and diagnostics for a broad range of
life-threating disease indications. The Company has offices in the
US and in Spain. ANEW's current
portfolio consists of three platforms - generic oncology drugs that
are in short supply in the US, Phase 3 ready biosimilar biologics
targeting cancer and autoimmune diseases, and its proprietary gene
therapy program using DNA and RNA as therapeutics and
diagnostics.
Important Information about the Proposed Business Combination
and Where to Find It
This press release relates to a proposed transaction between
Redwoods and ANEW. This press release does not constitute an offer
to sell or exchange, or the solicitation of an offer to buy or
exchange, any securities, nor shall there be any sale of securities
in any jurisdiction in which such offer, sale or exchange would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. In connection with the
proposed business combination, Redwoods, ANEW and/or a successor
entity of the transaction has filed relevant materials with the
SEC, including a registration statement on Form S-4 containing a
proxy statement/prospectus (the "Registration Statement"). The
Registration Statement includes a proxy statement/prospectus to be
distributed to holders of Redwoods's common stock in connection
with Redwoods's solicitation of proxies for the vote by Redwoods's
stockholders with respect to the proposed transaction and other
matters as described in the Registration Statement, as well as the
prospectus relating to the offer of securities to be issued to
ANEW's stockholders in connection with the proposed business
combination. The Registration Statement has been filed and declared
effective, and Redwoods [has mailed] a definitive proxy statement
to its stockholders.
Before making any voting or investment decision, investors and
security holders and other interested parties are urged to read the
Registration Statement, any amendments thereto and any other
documents filed with the SEC carefully and in their entirety when
they become available because they will contain important
information about Redwoods, ANEW and the proposed business
combination. Copies of these documents may be obtained free of
charge at the SEC's website at www.sec.gov.
The documents filed by Redwoods with the SEC also may be
obtained free of charge upon written request to Redwoods at c/o
Redwoods Acquisition Corp., 1115 Broadway 12th Floor, New York, NY 10010. The documents filed by
ANEW or any successor entity of the transaction with the SEC also
may be obtained free of charge upon written request to ANEW at
13576 Walnut Street, Suite A, Omaha,
NE 68144 USA.
Participants in the Solicitation
Redwoods and ANEW and their respective directors and executive
officers may be deemed participants in the solicitation of proxies
from Redwoods' stockholders with respect to the proposed business
combination under the rules of the SEC. Securityholders may obtain
more detailed information regarding the names, affiliations, and
interests of certain of Redwoods' executive officers and directors
in the solicitation by reading Redwoods' Registration Statement and
other relevant materials filed with the SEC in connection with the
proposed business combination when they become available.
Information about Redwoods' directors and executive officers and
their ownership of Redwoods common stock is set forth in its
prospectus related to its initial public offering dated
April 1, 2022. Other information
regarding the interests of Redwoods' participants in the proxy
solicitation, which in some cases, may be different than those of
their stockholders generally, will be set forth in the Registration
Statement relating to the proposed business combination when it
becomes available. These documents can be obtained free of charge
at the SEC's web site at www.sec.gov.
ANEW and its directors and executive officers may also be deemed
to be participants in the solicitation of proxies from the
stockholders of Redwoods in connection with the proposed business
combination. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
business combination will be included in the Registration Statement
for the proposed business combination.
Non-Solicitation
This press release is not a proxy statement or solicitation of a
proxy, consent, or authorization with respect to any securities or
in respect of the proposed business combination. This press release
shall also not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor shall there be any sale of
securities in any states or jurisdictions in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the Securities
Act of 1933, as amended, or an exemption therefrom.
Forward-Looking Statements - This press release contains
forward-looking statements. All statements other than statements of
historical facts are "forward-looking statements," including those
relating to future events. In some cases, forward-looking
statements can be identified by terminology such as "plan",
"expect", "anticipate", "may", "might", "will", "should",
"project", "believe", "estimate", "predict", "potential", "intend",
or "continue", or other words or terms of similar meaning. These
statements include, without limitation, statements related to
research, pr-clinical data, plans for future development, and the
potential of a drug development candidate. These forward-looking
statements are based on our current plans, objectives, estimates,
expectations and intentions, and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a results of these risks and
uncertainties, which include, without limitation, risks and
uncertainties with the COVID-19 pandemic and its impact on the
Company's clinical plans and business strategy, risks and
uncertainties associated with product development and clinical
success thereof, the uncertainties of regulatory approvals, and
manufacturing and supply risks, other risks and uncertainties
affecting the Company and its research and development programs as
set forth in its SEC filings. Other risks and uncertainties of
which the Company is not currently aware may also affect the
Company's forward-looking statements and may cause actual results
and the timing of events to differ materially from those
anticipated. The forward-looking statements herein are made only as
of the date hereof. The Company undertakes no obligation to update
or supplement any forward-looking statements to reflect actual
results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
Investor Contact - Info@anewmeds.com
ANEW MEDICAL, INC. – U.S. Phone (402) 239-5556
View original
content:https://www.prnewswire.com/news-releases/anew-medical-announces-key-patent-issued-in-china-to-protect-klotho-protein-and-gene-delivery-systems-302077883.html
SOURCE ANEW MEDICAL, INC.